

Supplementary Table 4. Association between each class of antihypertensive medication and clinical outcomes in patients with hypertension

Outcome	SARS-CoV-2 (+) with HTN (n = 1,609)			Matched population		
	No. of events	Adjusted OR (95% CI)	p value	No. of events	Adjusted OR (95% CI)	p value
RAS blocker				1,070 (535 pairs) ^a		
Death	165	0.81 (0.56–1.17)	0.265	127	0.88 (0.59–1.33)	0.545
ICU/death	378	0.95 (0.73–1.22)	0.669	276	1.05 (0.79–1.40)	0.720
O ₂ /ICU/death	614	1.01 (0.80–1.27)	0.956	439	0.99 (0.77–1.28)	0.939
Calcium-channel blocker				1,304 (652 pairs) ^a		
Death	165	0.87 (0.60–1.24)	0.437	130	1.05 (0.61–1.80)	0.875
ICU/death	378	1.01 (0.79–1.29)	0.943	304	1.15 (0.88–1.51)	0.305
O ₂ /ICU/death	614	1.07 (0.86–1.33)	0.556	502	1.17 (0.92–1.48)	0.208
Beta-blocker				508 (254 pairs) ^a		
Death	165	1.21 (0.78–1.89)	0.404	69	1.01 (0.57–1.78)	0.976
ICU/death	378	1.18 (0.86–1.61)	0.303	146	0.90 (0.60–1.36)	0.626
O ₂ /ICU/death	614	1.05 (0.79–1.40)	0.744	225	0.76 (0.52–1.10)	0.143
Diuretics				572 (286 pairs) ^a		
Death	165	1.12 (0.70–1.80)	0.637	56	1.21 (0.66–2.22)	0.544
ICU/death	378	0.90 (0.65–1.25)	0.532	128	0.85 (0.57–1.29)	0.453
O ₂ /ICU/death	614	0.86 (0.64–1.15)	0.301	211	0.82 (0.57–1.18)	0.293

Patients on each class of medication were matched to patients not using that medication according to propensity scores.

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; HTN, hypertension; OR, odds ratio; CI, confidence interval; RAS, renin-angiotensin system; ICU, intensive care unit.

^aNumber of matched population.